CVKD

Cadrenal Therapeutics, Inc. - Common Stock (CVKD)

About Cadrenal Therapeutics, Inc. - Common Stock (CVKD)

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Details

Daily high

$17.04

Daily low

$16.31

Price at open

$16.97

52 Week High

$22.90

52 Week Low

$5.70

Market cap

31.5M

Dividend yield

0.00%

Volume

10,448

Avg. volume

22,899

P/E ratio

-1.92

Cadrenal Therapeutics, Inc. - Common Stock News